Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HUTCHMED (China)HMDCF 66 Price-to-Tangible-Book is 1.49 as of Aug. 25, 2026. GuruFocus rates HMDCF with a GF Score™ of 66/100 and a GF Value™ of $2.39. The stock has 8 warning signs investors should review. Among 837 Drug Manufacturers companies, HUTCHMED (China) ranks better than 63.92% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
HUTCHMED (China) Price-to-Tangible-Book Related Terms
HUTCHMED (China) Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for HUTCHMED (China)'s Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HMDCF vs ZTS, UTHR, VTRS: Price-to-Tangible-Book Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, HUTCHMED (China)'s Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HUTCHMED (China) Price-to-Tangible-Book vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HUTCHMED (China)'s Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where HUTCHMED (China)'s Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
HUTCHMED (China) (HMDCF) has a Price-to-Tangible-Book of 1.49 as of Aug. 25, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on HUTCHMED (China) and its competitors. According to the industry distribution chart, HUTCHMED (China) ranks #302 out of 837 companies in the Drug Manufacturers industry, placing it in the top 36.1%.
Is HUTCHMED (China)'s Price-to-Tangible-Book too high?
HUTCHMED (China)'s current Price-to-Tangible-Book is 1.49. The Drug Manufacturers industry median Price-to-Tangible-Book is 2.24. HUTCHMED (China)'s value of 1.49 is 33.5% below this industry median. Based on the distribution chart, HUTCHMED (China) ranks #302 out of 837 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, HUTCHMED (China) has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does HUTCHMED (China)'s Price-to-Tangible-Book compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HUTCHMED (China) ranks #302 out of 837 companies for Price-to-Tangible-Book. This puts HUTCHMED (China) in the upper half of its industry. The industry median Price-to-Tangible-Book is 2.24. HUTCHMED (China)'s value of 1.49 is 33.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Drug Manufacturers company?
The median Price-to-Tangible-Book among Drug Manufacturers companies is 2.24, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HUTCHMED (China)'s current Price-to-Tangible-Book of 1.49 is 33.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on HUTCHMED (China) and its competitors. For the Drug Manufacturers industry, the median Price-to-Tangible-Book is 2.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HUTCHMED (China)'s current Price-to-Tangible-Book is 1.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HUTCHMED (China) stock overvalued right now?
HUTCHMED (China) (HMDCF) has a current Price-to-Tangible-Book of 1.49. The stock's GF Value™ is $2.39, compared to a current price of $2.16 — trading 9.6% below its estimated fair value. The current Price-to-Tangible-Book is 1.49 and 33.5% below the Drug Manufacturers industry median of 2.24. HUTCHMED (China)'s overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For HUTCHMED (China) (HMDCF), the current Price-to-Tangible-Book is 1.49 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HUTCHMED (China) (HMDCF) Overvalued in 2026?
Based on GuruFocus' analysis, HUTCHMED (China) stock appears to be undervalued.
The current stock price of $2.16 is trading 9.6% below its estimated GF Value™ of $2.39.
Key valuation signals for HMDCF:
Price-to-Tangible-Book: 1.49
GF Value™: $2.39 vs. price of $2.16 (9.6% below fair value)
Industry Position: 33.5% below the Drug Manufacturers median (#302 of 837)
No single metric tells the full story. See the HMDCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
66GF Score
Get the complete analysis for HMDCF
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HMDCF has been successfully added to your 
